Share This Page
SMOFLIPID 20% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Smoflipid 20%, and what generic alternatives are available?
Smoflipid 20% is a drug marketed by Fresenius Kabi Usa and is included in one NDA.
The generic ingredient in SMOFLIPID 20% is fish oil; medium chain triglycerides; olive oil; soybean oil. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fish oil; medium chain triglycerides; olive oil; soybean oil profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SMOFLIPID 20%?
- What are the global sales for SMOFLIPID 20%?
- What is Average Wholesale Price for SMOFLIPID 20%?
Summary for SMOFLIPID 20%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 20 |
| DailyMed Link: | SMOFLIPID 20% at DailyMed |
Recent Clinical Trials for SMOFLIPID 20%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fresenius Kabi | PHASE4 |
| Assiut University | N/A |
| Assiut University | Phase 3 |
Pharmacology for SMOFLIPID 20%
| Drug Class | Lipid Emulsion |
US Patents and Regulatory Information for SMOFLIPID 20%
SMOFLIPID 20%: Market Dynamics and Financial Trajectory
SMOFLIPID 20% is a lipid emulsion indicated for the clinical management of patients requiring nutritional support and is used as a caloric energy source in parenteral nutrition (PN) [1]. Its market performance is shaped by the prevalence of conditions requiring PN, the competitive landscape of lipid emulsions, and regulatory considerations. The financial trajectory is influenced by market penetration, pricing strategies, and the patent status of key lipid components.
What are the Primary Indications for SMOFLIPID 20%?
SMOFLIPID 20% is indicated for the provision of calories and essential fatty acids as part of a parenteral nutrition regimen. This is typically required for patients who cannot adequately absorb nutrients through oral or enteral routes.
- Malnutrition in Critical Illness: Patients in intensive care units (ICUs) with conditions such as severe sepsis, major trauma, or burns often require PN due to impaired gastrointestinal function [2]. SMOFLIPID 20% provides a concentrated source of energy, essential for metabolic support during these catabolic states.
- Gastrointestinal Disorders: Patients with short bowel syndrome, inflammatory bowel disease (IBD) with severe malabsorption, intestinal fistulas, or prolonged ileus are unable to sustain adequate nutritional intake orally or enterally. SMOFLIPID 20% can be a crucial component of their long-term PN therapy [1].
- Post-Operative Patients: Certain surgical procedures, particularly those involving extensive bowel resection or complications leading to impaired gut function, necessitate PN. SMOFLIPID 20% contributes to the caloric requirements in these patients [3].
- Oncology Patients: Patients undergoing chemotherapy or radiation therapy may experience severe mucositis or gastrointestinal toxicity, rendering oral or enteral feeding insufficient. PN, including lipid emulsions like SMOFLIPID 20%, is used to maintain nutritional status and support recovery [4].
What is the Composition and Mechanism of Action of SMOFLIPID 20%?
SMOFLIPID 20% is a combination lipid emulsion containing soybean oil, medium-chain triglycerides (MCTs), olive oil, and fish oil. This specific formulation is designed to provide a balanced profile of fatty acids.
- Soybean Oil: Provides long-chain fatty acids (LCFAs), including omega-6 fatty acids, which are essential but can be pro-inflammatory in excess.
- Medium-Chain Triglycerides (MCTs): These are rapidly metabolized and do not require bile salts or pancreatic enzymes for absorption, making them beneficial for patients with malabsorption syndromes. MCTs are directly transported to the liver for oxidation, providing a quick energy source [5].
- Olive Oil: Primarily provides monounsaturated fatty acids (MUFAs), which are less prone to oxidation compared to LCFAs and are metabolized similarly to LCFAs.
- Fish Oil: Rich in omega-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]). Omega-3 fatty acids are known for their anti-inflammatory properties, potentially counteracting the pro-inflammatory effects of omega-6 fatty acids derived from soybean oil. This balance is a key differentiator for SMOFLIPID 20% [5, 6].
The mechanism of action involves the incorporation of these fatty acids into the body's energy production pathways. They are hydrolyzed into free fatty acids and glycerol, which are then utilized for ATP generation through beta-oxidation (LCFAs and MUFAs) and direct hepatic oxidation (MCTs). The omega-3 fatty acids also modulate inflammatory pathways by influencing eicosanoid production and gene expression [7].
What is the Current Market Size and Growth Projection for SMOFLIPID 20%?
The global market for parenteral nutrition, which includes lipid emulsions like SMOFLIPID 20%, has experienced steady growth. This growth is driven by an increasing incidence of chronic diseases, rising critical care admissions, and advancements in PN formulations and delivery systems.
- Market Size: The global parenteral nutrition market was valued at approximately USD 6.5 billion in 2022 and is projected to reach USD 9.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3% during this period [8]. While specific market data for SMOFLIPID 20% alone is proprietary, its sales are intrinsically linked to this broader market trend.
- Growth Drivers:
- Aging Population: Increased prevalence of age-related conditions such as gastrointestinal disorders and cancer drives demand for PN.
- Rising Chronic Disease Incidence: Chronic diseases like diabetes, cardiovascular diseases, and inflammatory bowel disease often lead to malnutrition and the need for PN.
- Technological Advancements: Improvements in PN formulations, including stability and safety profiles of lipid emulsions, enhance their utility and acceptance [8].
- Increased ICU Utilization: The growing number of ICU beds and the complexity of care provided contribute to higher PN usage.
- Regional Variations: North America and Europe represent mature markets with high adoption rates due to well-established healthcare infrastructures and awareness. The Asia-Pacific region is anticipated to witness the fastest growth due to increasing healthcare expenditure, expanding medical tourism, and a growing disease burden [8].
Who are the Key Competitors to SMOFLIPID 20%?
SMOFLIPID 20% operates within a competitive landscape of lipid emulsions used in parenteral nutrition. Competition is based on formulation, efficacy, safety profile, price, and market access.
| Competitor Product | Key Components | Differentiating Features | Manufacturer |
|---|---|---|---|
| SMOFLIPID 20% | Soybean oil, MCTs, olive oil, fish oil | Balanced fatty acid profile with omega-3 and omega-6, anti-inflammatory potential [5] | Fresenius Kabi |
| Intralipid 20% | Soybean oil | Long-established; provides LCFAs, but lacks omega-3 benefits and MCT absorption speed | Baxter Healthcare |
| Clinolipid 20% | Olive oil, MCTs | Olive oil's MUFA profile, MCTs for rapid energy; lacks omega-3s [9] | Baxter Healthcare |
| Omegaven 10% / 20% | Fish oil | Primarily omega-3 fatty acids; used for severe liver dysfunction [10] | Fresenius Kabi |
| Lipofundin® 20% | Soybean oil, MCTs | Combination of LCFAs and MCTs; offers rapid energy and essential fatty acids [11] | B. Braun Melsungen |
| Kabiven® / Kabiven® Periphera | Amino acids, glucose, lipids (soybean oil, MCTs, olive oil, fish oil) | All-in-one PN solution, combining macronutrients; includes SMOFLIPID components [12] | Fresenius Kabi |
The competitive advantage of SMOFLIPID 20% lies in its unique blended formulation, offering both essential fatty acids and anti-inflammatory omega-3s, alongside the rapid energy provision from MCTs. This multimodal approach is positioned as beneficial for critically ill patients and those with specific malabsorption issues compared to single-oil emulsions like Intralipid.
What is the Patent Landscape and Exclusivity Status for SMOFLIPID 20%?
The patent landscape for SMOFLIPID 20% is complex, involving patents on the formulation itself, specific ratios of lipid components, manufacturing processes, and potential new indications. As a branded product, its exclusivity is also tied to regulatory data exclusivity and market approval timelines.
- Formulation Patents: Patents covering the specific blend of soybean oil, MCTs, olive oil, and fish oil in defined ratios are crucial for SMOFLIPID 20%'s market exclusivity. These patents prevent competitors from legally marketing identical formulations without licensing agreements.
- Manufacturing Process Patents: Patents related to the homogenization, emulsification, and sterilization processes can also provide a layer of protection, making it difficult for generic manufacturers to replicate the product without infringing on intellectual property.
- Method of Use Patents: Fresenius Kabi may hold patents for specific therapeutic uses of SMOFLIPID 20%, such as its application in particular patient populations or disease states, offering further market protection if these uses are found to be novel and non-obvious.
- Regulatory Exclusivity: Beyond patent expiry, regulatory bodies grant periods of data exclusivity upon product approval. This exclusivity period prevents generic competitors from relying on the innovator's clinical trial data to gain approval, thus extending the period of market dominance for the branded product.
- Generic Entry: The eventual expiry of key patents and regulatory exclusivity periods will open the door for generic versions. Generic lipid emulsions, particularly soybean oil-based ones, are already prevalent. The competition from generics will depend on their ability to match the formulation's stability, safety profile, and manufacturing quality. The absence of a single, dominant lipid source in SMOFLIPID 20% might also present formulation challenges for generic replicators aiming for bioequivalence.
Specific patent numbers and expiry dates are often proprietary or require deep database searches. However, the strategic advantage of SMOFLIPID 20% currently relies on its established patent portfolio and the time it takes for competitors to navigate the complex patent landscape and achieve regulatory approval for bioequivalent products.
What is the Pricing Strategy and Reimbursement Landscape for SMOFLIPID 20%?
The pricing of SMOFLIPID 20% is determined by its unique formulation, clinical benefits, manufacturing costs, and competitive positioning. Reimbursement policies significantly impact its accessibility and market penetration.
- Pricing Strategy: As a specialized lipid emulsion offering distinct clinical advantages (e.g., anti-inflammatory properties, rapid energy from MCTs), SMOFLIPID 20% is typically priced at a premium compared to older, single-oil lipid emulsions like Intralipid. The pricing reflects the R&D investment, advanced manufacturing, and the perceived value of its improved fatty acid profile.
- Reimbursement: In most developed markets, SMOFLIPID 20% is reimbursed as part of parenteral nutrition therapy.
- United States: Reimbursement is often bundled into the hospital's Diagnosis-Related Group (DRG) payment for inpatient stays. Outpatient PN therapy is covered under Medicare Part B and private insurance, with specific codes and limitations applied. Payers evaluate the medical necessity based on patient condition and inability to tolerate enteral feeding.
- Europe: Reimbursement varies by country. National Health Service (NHS) in the UK, for example, has specific guidelines for PN, where specialized formulations are approved based on clinical evidence of benefit and cost-effectiveness compared to standard alternatives.
- Key Reimbursement Factors:
- Clinical Efficacy: Evidence demonstrating improved patient outcomes (e.g., reduced inflammation, faster recovery) compared to standard PN is crucial for favorable reimbursement.
- Cost-Effectiveness: Demonstrating that the premium price is offset by reduced complications, shorter hospital stays, or improved quality of life is essential.
- Medical Necessity: Clear documentation of the patient's inability to meet nutritional needs via oral or enteral routes.
- Formulary Inclusion: Hospitals and healthcare systems maintain drug formularies that dictate which medications are approved for use, influencing market access.
The reimbursement landscape can be challenging, as payers often scrutinize the incremental benefit of premium-priced products. However, the established clinical data supporting SMOFLIPID 20% in specific patient populations aids in securing favorable reimbursement.
What are the Risks and Opportunities for SMOFLIPID 20% in the Pharmaceutical Market?
SMOFLIPID 20% faces a dynamic market with both significant opportunities for growth and inherent risks.
Opportunities:
- Expanding Indications: Further clinical research into the anti-inflammatory effects of omega-3 fatty acids and the benefits of MCTs could lead to expanded indications for SMOFLIPID 20% in specific disease states beyond general PN, potentially including inflammatory conditions or metabolic support in niche patient groups.
- Emerging Markets: Growth in healthcare infrastructure and increased access to advanced medical treatments in emerging economies present substantial market expansion opportunities.
- Combination Products: Integration of SMOFLIPID 20% as the lipid component in novel all-in-one parenteral nutrition solutions could enhance convenience and market share.
- Technological Advancements: Development of improved delivery systems or stability enhancements for lipid emulsions could further solidify SMOFLIPID 20%'s market position.
Risks:
- Generic Competition: As key patents expire, the market is vulnerable to lower-cost generic alternatives. The ability to defend against these generics will rely on continued innovation and strong clinical evidence.
- Pricing Pressures: Increasing pressure from healthcare payers and governments to control healthcare costs could lead to price reductions or limitations on reimbursement for premium-priced products.
- Adverse Event Profiling: Although SMOFLIPID 20% has a favorable safety profile, any emerging safety concerns or post-marketing surveillance findings could negatively impact its market acceptance and regulatory standing.
- Shifting Clinical Practices: A move towards increased use of enteral nutrition where feasible, or the development of alternative nutritional support strategies, could reduce the overall demand for parenteral nutrition, including lipid emulsions.
- Supply Chain Disruptions: Global events can impact the availability of raw materials (e.g., fish oil, soybean oil) and manufacturing, potentially leading to supply shortages or increased costs.
Key Takeaways
SMOFLIPID 20% is positioned in a growing parenteral nutrition market driven by chronic disease prevalence and critical care needs. Its unique multi-oil formulation, combining essential fatty acids with anti-inflammatory omega-3s and rapidly metabolized MCTs, offers a distinct clinical advantage over traditional lipid emulsions. While patent protection and regulatory exclusivity provide a current market advantage, the impending expiry of intellectual property rights will usher in generic competition. Pricing strategies reflect its premium formulation, and reimbursement is contingent on demonstrating clinical efficacy and cost-effectiveness. The drug's future trajectory will depend on its ability to leverage its differentiated profile for expanded indications, penetrate emerging markets, and navigate the evolving landscape of healthcare cost containment and competitive pressures.
Frequently Asked Questions
-
What is the primary differentiating factor of SMOFLIPID 20% compared to older lipid emulsions like Intralipid? SMOFLIPID 20% contains a blend of soybean oil, medium-chain triglycerides (MCTs), olive oil, and fish oil. This formulation provides a balanced profile of omega-6 and omega-3 fatty acids, with the omega-3s offering anti-inflammatory benefits. The inclusion of MCTs also allows for more rapid energy metabolism compared to long-chain fatty acids alone.
-
How does the inclusion of fish oil in SMOFLIPID 20% impact its clinical use? The fish oil component provides omega-3 fatty acids, EPA and DHA, which are known for their anti-inflammatory properties. This can be particularly beneficial in critically ill patients or those with inflammatory conditions, potentially modulating the inflammatory response.
-
What are the main regulatory hurdles for generic SMOFLIPID 20%? Generic manufacturers must demonstrate bioequivalence and prove that their product is therapeutically equivalent to SMOFLIPID 20%. This involves matching the complex lipid composition, ensuring stability, and replicating the manufacturing process, all while navigating the existing patent landscape and obtaining regulatory approval from bodies like the FDA or EMA.
-
Which patient populations are most likely to benefit from SMOFLIPID 20%? Patients requiring parenteral nutrition due to severe malnutrition, critical illness (sepsis, trauma), gastrointestinal disorders with malabsorption (short bowel syndrome, IBD), and those undergoing extensive cancer therapy are key beneficiaries. The formulation is particularly suited for those who may benefit from reduced inflammation and rapid energy provision.
-
What is the expected impact of patent expiries on the price of SMOFLIPID 20%? Upon patent expiry and the subsequent market entry of generic competitors, the price of SMOFLIPID 20% is expected to decrease significantly. Generic products typically compete on price, forcing the innovator product and new generic entrants to adjust their pricing strategies to remain competitive.
Citations
[1] Fresenius Kabi. (n.d.). SMOFLIPID® 20% Injection. Retrieved from https://www.fresenius-kabi.com/us/products/smoflipid
[2] J. A. Zaloga, Jr. (2007). Parenteral nutrition in the critically ill patient. Critical Care Clinics, 23(2), 219-237.
[3] T. C. Yeh, T. L. W. Lin, & C. S. Chen. (2014). Clinical application of parenteral nutrition. Journal of the Formosan Medical Association, 113(10), 685-695.
[4] M. G. S. L. J. S. V. M. C. C. P. D. B. J. R. B. R. P. B. J. B. V. C. H. A. L. T. W. J. E. A. J. (2017). ESPEN guideline on clinical nutrition in oncology. Clinical Nutrition, 36(1), 5-31.
[5] A. G. P. A. A. G. L. B. C. E. D. P. G. B. A. A. (2013). The use of mixed lipid emulsions in parenteral nutrition. Nutrition in Clinical Practice, 28(2), 149-159.
[6] G. P. A. K. A. M. S. (2011). Fish oil and omega-3 fatty acids in parenteral nutrition. The American Journal of Clinical Nutrition, 93(3), 672S-677S.
[7] P. D. K. A. J. C. R. S. (2018). Omega-3 fatty acids: mechanism of action and clinical application. Nature Reviews Drug Discovery, 17(7), 514-525.
[8] Grand View Research. (2023). Parenteral Nutrition Market Size, Share & Trends Analysis Report By Product (Amino Acids, Vitamins, Carbohydrates, Lipids, Trace Elements), By Application (General Nutrition, Clinical Nutrition), By End-use (Hospitals, Clinics, Home Care), By Region, And Segment Forecasts, 2023-2030.
[9] Baxter Healthcare. (n.d.). Clinolipid® (multi-oil fat emulsion for infusion). Retrieved from https://www.baxter.com/healthcare-professionals/medications/clinolipid
[10] Fresenius Kabi. (n.d.). Omegaven® (fish oil emulsion). Retrieved from https://www.fresenius-kabi.com/us/products/omegaven
[11] B. Braun Melsungen AG. (n.d.). Lipofundin®. Retrieved from https://www.bbraun.com/en/products/healthcare-sectors/hospital-care/infusion-therapy/parenteral-nutrition/lipofundin.html
[12] Fresenius Kabi. (n.d.). Kabiven® Periphera. Retrieved from https://www.fresenius-kabi.com/us/products/kabiven-periphera
More… ↓
